children
live
area
stabl
plasmodium
falciparum
transmiss
acquir
substanti
protect
immun
malaria
first
decad
life
protect
mediat
larg
extent
variant
surfac
antigen
vsa
specif
igg
nevertheless
women
area
remain
highli
suscept
p
falciparum
infect
becom
pregnant
parasit
switch
express
particular
vsa
call
vsapam
allow
infect
erythrocyt
ie
sequestr
placenta
compat
parasit
surviv
nonpregn
host
acquir
immun
pam
mediat
vsapamspecif
igg
either
opson
i
phagocytosi
interfer
chondroitin
sulphat
csa
specif
adhes
i
member
p
falciparum
erythrocyt
membran
protein
famili
vsa
appear
domin
pregnancyassoci
plasmodium
falciparum
malaria
pam
type
vsa
p
falciparum
genom
therefor
main
target
current
effort
develop
vaccin
pam
assist
work
develop
panel
vsapamspecif
human
monoclon
antibodi
opson
vsapamexpress
i
phagocytosi
interfer
ie
adhes
csa
barfod
et
al
unpublish
data
antibodi
use
enrich
vsapam
express
parasit
express
vsapam
obtain
women
pam
present
studi
use
two
abovement
monoclon
antibodi
select
vsapam
express
parasit
nonpregn
donor
one
antibodi
chosen
appear
react
parasit
express
vsapam
antibodi
chosen
react
welldefin
interclon
variant
epitop
domain
use
eight
vsapamspecif
monoclon
antibodi
gener
describ
elsewher
vsapam
defin
ie
surfaceexpress
vsa
significantli
better
recogn
plasma
igg
p
falciparumexpos
multigravida
sympatr
men
recognit
plasma
igg
men
significantli
differ
recognit
plasma
igg
nonexpos
control
contrast
typic
nonpam
vsa
better
recogn
plasma
igg
p
falciparumexpos
adult
nonexpos
donor
without
mark
sexdepend
differ
seven
monoclon
antibodi
use
specif
interclon
variant
epitop
either
domain
exact
specif
last
antibodi
remain
undefin
appear
recogn
conform
possibl
discontinu
epitop
difficult
reproduc
recombin
construct
recogn
vsapam
express
p
falciparum
genotyp
wherea
epitop
recogn
present
p
falciparum
clone
opson
vsapamexpress
i
phagocytosi
interfer
adhes
csa
barfod
et
al
prepar
use
two
longterm
vitroadapt
parasit
clone
origin
deriv
parasit
isol
dutch
girl
near
amsterdam
airport
chosen
select
express
vsapam
react
clone
hondura
icdc
parasit
strain
chosen
select
express
vsapam
reactiv
parasit
grown
erythrocyt
describ
select
vsapam
express
done
essenti
describ
elsewher
brief
monoclon
antibodi
immobil
protein
acoat
magnet
bead
dynal
mix
i
adher
antibodyco
bead
isol
strong
magnet
field
subsequ
return
vitro
cultur
select
protocol
repeat
multipl
antibodyselect
parasit
allow
vsa
express
assess
flow
cytometri
analysi
describ
elsewher
use
plasma
p
falciparumexpos
multigravida
sympatr
men
nonexpos
control
assess
sexspecif
vsa
recognit
accord
origin
criteria
sexspecif
recognit
requir
level
iesurfac
reactiv
igg
significantli
higher
p
falciparumexpos
multigravida
sympatr
men
ii
differ
igg
level
p
falciparumexpos
men
nonexpos
control
statist
signific
use
term
plasma
p
falciparumexpos
women
pregnant
first
time
third
time
fifth
time
assess
paritydepend
requir
statist
signific
relationship
igg
level
number
pregnanc
p
falciparumexpos
women
parasit
isol
consid
express
vsapam
plasma
igg
recognit
i
sexspecif
paritydepend
latestag
i
isol
magnet
separ
describ
return
cultur
overnight
obtain
ringstag
i
genom
dna
isol
qiaamp
blood
kit
qiagen
total
rna
extract
trizol
invitrogen
treat
dnase
invitrogen
min
absenc
dna
rna
sampl
confirm
describ
revers
transcript
perform
use
superscript
ii
invitrogen
random
hexam
primer
follow
realtim
pcr
quantifi
var
transcript
abund
describ
use
primer
pair
specif
vargen
genom
var
gene
genom
tabl
support
inform
latter
test
genom
dna
dilut
ascertain
appropri
fragment
size
melt
temperatur
amplif
effici
compar
intern
control
seryltrna
synthetas
primer
pair
vari
less
two
ct
valu
intern
control
amplifi
singl
fragment
expect
size
differ
antibodi
level
among
plasma
p
falciparumexpos
multigravida
p
falciparumexpos
men
nonexpos
control
donor
analys
oneway
anova
oneway
analysi
rank
nonnorm
distribut
data
statist
signific
p
overal
differ
detect
signific
pairwis
differ
isol
holmsidak
dunn
test
normal
nonnormaldistribut
data
respect
paritydepend
analys
pearson
product
moment
correl
vsa
express
surfac
unselect
significantli
better
recogn
plasma
igg
p
falciparumexpos
donor
sex
igg
nonexpos
donor
wherea
level
expos
men
multigravida
significantli
differ
furthermor
ie
surfacereact
igg
level
depend
pariti
tabl
figur
thu
unselect
show
typic
nonpamtyp
plasma
antibodi
recognit
pattern
ie
surfaceexpress
vsa
confirm
nonreact
eight
vsapamspecif
monoclon
antibodi
figur
vsa
express
reassess
three
round
select
week
first
round
select
recognit
select
either
show
indetermin
vsa
phenotyp
one
criteria
sexspecif
antibodi
recognit
met
tabl
figur
remain
nonreact
four
monoclon
antibodi
use
test
time
wherea
three
parasit
line
show
reactiv
least
one
figur
result
suggest
round
select
might
lead
definit
vsapam
express
least
inde
well
acquir
typic
sexspecif
pariti
depend
vsapam
express
pattern
four
addit
round
select
tabl
figur
react
monoclon
antibodi
except
figur
contrast
select
seven
time
reactiv
retain
indetermin
sexspecif
pattern
also
seen
three
round
select
acquir
paritydepend
pattern
typic
vsapamexpress
line
tabl
react
eight
vsapamspecif
monoclon
antibodi
figur
thu
could
use
select
vsapam
reactiv
consist
absenc
predict
epitop
antibodi
domain
parasit
transcript
constitut
total
measur
var
gene
transcript
unselect
parasit
increas
seven
round
select
contrast
select
affect
proport
transcript
figur
genom
contain
two
paralog
unselect
parasit
transcript
constitut
measur
var
transcript
increas
seven
round
select
respect
figur
transcript
level
gene
increas
seven
round
select
respect
figur
var
transcript
show
mark
chang
therefor
domin
transcript
parasit
follow
antibodi
select
domin
transcript
rel
select
suggest
domain
protein
encod
might
recogn
wherea
correspond
domain
encod
might
c
recogn
howev
encod
ident
amino
acid
sequenc
region
span
epitop
sequenc
figur
transcript
may
therefor
reflect
founder
effect
vsa
subset
vsapam
express
p
falciparum
involv
pregnancyassoci
malaria
pam
vsapamspecif
igg
mediat
acquir
immunolog
protect
pam
variant
appear
main
target
antibodi
therefor
lead
candid
develop
vaccin
pam
use
monoclon
human
igg
antibodi
select
erythrocyt
infect
two
genotyp
distinct
laboratori
p
falciparum
clone
deriv
nonpregn
donor
express
vsapam
parasit
acquir
express
vsapam
follow
select
show
increas
level
transcript
encod
variant
appear
pamtyp
vsa
p
falciparum
genom
result
obtain
studi
import
sever
reason
first
support
hypothesi
p
falciparum
parasit
capac
express
vsapam
hypothesi
support
previous
publish
data
p
falciparum
genom
appear
contain
least
one
paralog
gene
encod
known
vsapamtyp
antigen
furthermor
gene
select
transcrib
placent
parasit
follow
select
adhes
csa
vitro
express
ie
surfac
second
indic
p
falciparum
parasit
regularli
spontan
switch
express
vsapam
absenc
extern
signal
exampl
pregnancyassoci
hormon
chang
specul
switch
vsapam
express
requir
signal
pregnant
host
exampl
hormon
select
therefor
might
possibl
unless
parasit
deriv
host
also
argu
select
parasit
pan
csa
vitro
might
result
express
antigen
dubiou
relev
antigen
express
result
vivo
select
occur
pregnant
woman
data
show
switch
express
genuin
vsapam
occur
vitro
absenc
extern
signal
line
recent
evid
extens
find
suggest
switch
vsapam
vivo
also
occur
spontan
regardless
pregnanc
statu
host
pregnant
host
parasit
often
select
advantag
frequent
absenc
vsapamspecif
immun
women
low
pariti
wherea
appear
unabl
surviv
nonpregn
host
third
result
support
hypothesi
although
interclon
variat
result
antibodydriven
posit
select
divers
function
import
antibodi
epitop
molecul
constrain
thu
parasit
express
without
vulner
recognit
certain
antibodi
variat
defin
part
persist
nonrecognit
case
point
time
antibodi
origin
identifi
reactiv
vsapamexpress
effect
select
vsapam
express
genet
unrel
clone
signific
find
underscor
fact
effici
opson
i
phagocytosi
well
interfer
ie
adhes
csa
barfod
et
al
prepar
studi
also
corrobor
exist
evid
recogn
vsapamexpress
parasit
recogn
function
highli
constrain
conformationdepend
discontinu
epitop
like
opsonin
capabl
interf
ie
adhes
csa
barfod
et
al
prepar
therefor
epitop
highli
attract
candid
develop
pamspecif
vaccin
character
matter
highest
prioriti
current
research
although
theoret
possibl
anoth
target
remain
avail
evid
point
conclus
evid
support
current
effort
develop
pamspecif
vaccin
base
highlight
versatil
human
monoclon
antibodi
gener
clinic
immun
donor
investig
